MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies

• Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells.
• The new data strengthens previous promising findings shared at the Society for Immunotherapy of Cancer (SITC) conference in November 2023 and supports further development and advancement of MaaT034 toward clinical trials.

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer, will present new in vitro data at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place on April 5-10 in San Diego, California.

MaaT034, a ground-breaking full ecosystem synthetic microbiota product, is the first candidate coming​ from the​ Company’s MET-C platform. Produced using a co-culturing technology and for large scale manufacturing, MaaT034 is being developed to improve responses to immunotherapy for patients with solid tumors in combination with an ICI (Immune Checkpoint Inhibitors) treatment. The first-in-human study is planned for 2025, with clinical batches currently being produced in 2024.

The Company will detail the new preclinical data in a press release on Monday, April 8^th, 2024.

AACR Poster Presentation details:

• Title: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
• Session Category: Immunology
• Session Title: Microbiome, Inflammation, and Cancer
• Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30 PM
• Location: Poster Section 2
• Poster Board Number: 18
• Published Abstract Number: 6687

About MaaT Pharma

MaaT Pharma, a clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319207572/en/